Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
- Registration Number
- NCT01424462
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving. The study involves all volunteers receiving all 3 different formulations, as a single dose, and there is no placebo (dummy-drug; no active ingredient) in this study. Volunteers will also receive a single dose of a formulation used in previous trials (reference formulation), so as a proper comparison with the new formulations can be made. One of the new formulations will also be administered along with food, to assess if the drug performs or is absorbed differently.
- Detailed Description
The present study will investigate the tolerability and pharmacokinetics of single oral doses of firategrast administered as the existing immediate release tablet formulation and as three modified release tablet formulations designed to release drug over differing relase rates. The range of release rates is expected to give preliminary information on the performance of a matrix modified release formulation for use in future efficacy studies.
Subjects will receive each formulation in the fasted state in a randomised 4-part single dose crossover fashion. Based on the review of pharmacokinetic data from at least the first two study sessions, subjects may also receive a fifth dose of firategrast, administered after a high fat meal. The formulation administered with food will be chosen based upon pharmacokinetic data from previous dose sessions. Doses administered will be different with respect to gender; the doses are expected to result in similar exposures across the genders.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Male or female, aged 18 to 65 yrs inclusive
- Healthy, as determined by study physician
- Capable of giving informed consent
- Positive drugs of abuse result
- Positive for HIV or Hepatitis B and/or C viruses
- History of alcohol consumption in excess of average recommended weekly intake (more than 21 units for males, more than 14 units for females)
- Participation in a clinical trial within 90 days of scheduled first dose
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Firategrast XRA B Low extended release tablet Firategrast XRB C Medium extended releast tablet Firategrast XRC D High extended release tablet Firategrast IR A Immediate Release reference tablet
- Primary Outcome Measures
Name Time Method Systemic concentration & AUC of study drug pre-dose, up to 120 hours after each single dose
- Secondary Outcome Measures
Name Time Method Adverse events from screening, through study day, and up to follow-up visit. Spontaneous reporting Systemic concentration & AUC of study drug metabolite pre-dose, up to 120 hours after each single dose Vital signs screening, pre-dose, up-to 15 hours post does, follow-up visit 12-lead Electrocardiogram screening, pre-dose and up to 8 hours post dose, then at follow-up Heamatology, clinical chemistry and Uninalysis screening, predose, up-to 8 hours post dose, follow-up Blood samples for standard clinical safety monitoring, and unine samples
Trial Locations
- Locations (1)
GSK Investigational Site
🇦🇺Randwick, New South Wales, Australia